SAN FRANCISCO, May 8 /PRNewswire/ -- Sofinnova Ventures, a venture
capital firm investing in early-stage life science and information
technology companies, today announced the addition of industry veteran Bill
Ringo to its life science team. In his role as Executive-in-Residence, Bill
will apply his experience to help start new pharmaceutical companies and
guide existing companies and their management teams. The
Executive-in-Residence program is one of the resources Sofinnova Ventures
employs to steer start-ups to success.
"Bill has had a long relationship with Sofinnova through his
involvement with the companies we have invested in, and we are thrilled to
have him join us on a formal basis," said Jim Healy, MD, Ph.D., and General
Partner of Sofinnova Ventures. "Our portfolio companies and their
management teams will reap the benefits of Bill's personal experience in
launching products and building companies that feature outstanding product
development, commercial, and operational expertise. Bill has a wealth of
knowledge in working in both large pharmaceutical companies and
biotechnology companies, and is a major asset to Sofinnova's team and our
focus on financing spin outs."
New Executive-in-Residence Appointment
Bill Ringo has 35 years of experience in building compelling companies
developing new therapeutics for the treatment of life threatening diseases.
Bill is the former President and Chief Executive Officer of Abgenix, Inc.,
which sold for $2.7 billion to Amgen in April 2006. Abgenix focused on
developing human antibodies as agents to treat severe diseases such as
cancer. Vectibix, developed to treat colorectal cancer, was Abgenix's first
product launched by Amgen in 2006. Bill also serves as Chairman of the
Board of Directors at Intermune, a biopharmaceutical company focused on
developing and commercializing innovative therapies in pulmonology and
hepatology. From June 2003 to September 2003, he also served as Intermune's
interim President and CEO. Prior to these positions, Bill worked at Eli
Lilly & Company and served in various capacities including: Product Group
President, Oncology and Critical Care Products from June 1999 until his
retirement in February 2001; President of Internal Medicine Products from
January 1998 until June 1999; and President of Eli Lilly's Infectious
Diseases Business Unit from September 1995 until January 1998.
Bill is a member of the Board of Directors of Inspire Pharmaceuticals,
Allos Therapeutics, and Portola Pharmaceuticals. He holds a B.S. and an
M.B.A. from the University of Dayton.
About Sofinnova Ventures
Founded in 1974, Sofinnova Ventures is a leading venture capital firm
specializing in spin offs and emphasizing a diversified investment strategy
through the financing of early stage companies in the life science and
information technology sectors. Sofinnova's mission is to create value by
providing entrepreneurs with the resources, experience and networks
necessary to turn their ideas into profitable businesses. For more
information, visit www.sofinnova.com.
SOURCE Sofinnova Ventures